Compositions and methods for treating bone diseases
Certain aspects of the present invention generally relate to compositions and methods for treating a bone disease, for example a genetic bone disease. In one embodiment the bone disease is fibular hemimelia, proximal femoral focal deficiency, tarsal coalition or humeroradial synostosis.
1. A method for treating an orthopedic disease, comprising administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an inhibitor of beta-catenin signaling, wherein the orthopedic disease is fibular hemimelia.
2. The method of claim 1 , wherein the composition is administered in-utero.
3. The method of claim 2 , wherein the composition is administered in the third trimester of pregnancy.
4. The method of claim 1 , wherein the composition is administered after birth of the subject.
5. The method of claim 1 , wherein the subject is a subject having an elevated level of beta-catenin signaling.
6. The method of claim 1 , wherein the inhibitor of beta-catenin signaling is selected from the group consisting of LGK-974, IWP-2, iCRT 3, iCRT 14, ICG 001, XAV-939, KY02111, and a combination of at least two thereof.
7. The method of claim 6 , wherein the inhibitor of β-catenin signaling is iCRT 14.
8. The method of claim 6 , wherein the inhibitor of β-catenin signaling is XAV-939.
9. The method of claim 6 , wherein the inhibitor of β-catenin signaling is LGK-974.
10. The method of claim 6 , wherein the inhibitor of β-catenin signaling is iCRT 3.
11. The method of claim 6 , wherein the inhibitor of β-catenin signaling is IWP-2.
12. The method of claim 6 , wherein the inhibitor of β-catenin signaling is ICG 001.
13. The method of claim 6 , wherein the inhibitor of β-catenin signaling is KY02111.